Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/rel...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2021-03-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8780 |
id |
doaj-2c55f0ed380e4f6599a61dbcd9afff9a |
---|---|
record_format |
Article |
spelling |
doaj-2c55f0ed380e4f6599a61dbcd9afff9a2021-03-06T11:41:19ZengPAGEPress PublicationsHematology Reports2038-83222038-83302021-03-0113110.4081/hr.2021.8780Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approachPanayotis Kaloyannidis0Eshrak Al Shaibani1Asif Moinnudin2Khalid Al Anezi3Hani Al Hashmi4Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, DammamDepartment of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, DammamMedical Imaging, King Fahad Specialist Hospital, DammamDepartment of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, DammamDepartment of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity. https://www.pagepress.org/journals/index.php/hr/article/view/8780Allogeneic hematopoietic stem cell transplantation, Hodgkin lymphoma, programmed death-1 (PD-1) inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Panayotis Kaloyannidis Eshrak Al Shaibani Asif Moinnudin Khalid Al Anezi Hani Al Hashmi |
spellingShingle |
Panayotis Kaloyannidis Eshrak Al Shaibani Asif Moinnudin Khalid Al Anezi Hani Al Hashmi Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach Hematology Reports Allogeneic hematopoietic stem cell transplantation, Hodgkin lymphoma, programmed death-1 (PD-1) inhibitors |
author_facet |
Panayotis Kaloyannidis Eshrak Al Shaibani Asif Moinnudin Khalid Al Anezi Hani Al Hashmi |
author_sort |
Panayotis Kaloyannidis |
title |
Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach |
title_short |
Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach |
title_full |
Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach |
title_fullStr |
Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach |
title_full_unstemmed |
Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach |
title_sort |
repeated courses of escalating doses of nivolumab in refractory hodgkin lymphoma with recurrent relapses post allografting: a safe and effective treatment approach |
publisher |
PAGEPress Publications |
series |
Hematology Reports |
issn |
2038-8322 2038-8330 |
publishDate |
2021-03-01 |
description |
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity.
|
topic |
Allogeneic hematopoietic stem cell transplantation, Hodgkin lymphoma, programmed death-1 (PD-1) inhibitors |
url |
https://www.pagepress.org/journals/index.php/hr/article/view/8780 |
work_keys_str_mv |
AT panayotiskaloyannidis repeatedcoursesofescalatingdosesofnivolumabinrefractoryhodgkinlymphomawithrecurrentrelapsespostallograftingasafeandeffectivetreatmentapproach AT eshrakalshaibani repeatedcoursesofescalatingdosesofnivolumabinrefractoryhodgkinlymphomawithrecurrentrelapsespostallograftingasafeandeffectivetreatmentapproach AT asifmoinnudin repeatedcoursesofescalatingdosesofnivolumabinrefractoryhodgkinlymphomawithrecurrentrelapsespostallograftingasafeandeffectivetreatmentapproach AT khalidalanezi repeatedcoursesofescalatingdosesofnivolumabinrefractoryhodgkinlymphomawithrecurrentrelapsespostallograftingasafeandeffectivetreatmentapproach AT hanialhashmi repeatedcoursesofescalatingdosesofnivolumabinrefractoryhodgkinlymphomawithrecurrentrelapsespostallograftingasafeandeffectivetreatmentapproach |
_version_ |
1724229710613839872 |